OCULGEN, InnoStar's partner in excellence, has announced that its proprietary FIC bispecific antibody fusion protein OCUL101 has been approved by the U.S. FDA for the clinical trial.
InnoStar is proud to have participated in the development process of this excellent project, providing the full suite of Non-clinical pharmacokinetics and Non-clinical toxicological assessment services, in strict compliance with FDA guidelines for GLP and in compliance with FDA standards. A series of scientific, systematic and high-quality trial programs have been formulated to support the R&D process of OCULGEN and jointly promote the project smoothly.
Address: 199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, China
Postcode: 201203
Tel: +86-21-60211999
services@innostar.cn
86-021-xxxxxxx
Scan the QR code
Subscription to our Wechat account
Copyright © 2017-2021©中国·手机球探(bet007认证)官方网站-Macau App Station. All Rights Reserved. Created By VPABrand.com
